9 Hrs
Source:
معلومات مباشر
Source: معلومات مباشر
9 Hrsمعلومات مباشر
Source: معلومات مباشر
9 HrsReady to play
Ready to play
Eli Lilly shares rose 2.8% in premarket trading Thursday after Chinese regulators approved its oral weight-loss drug, orforglipron. The approval gives the company an edge over Novo Nordisk in the Chinese market, as the oral version of Wegovy has not been approved in Beijing. The drug is aimed at patients who prefer pills to injections.
Notice: This Is an AI-Generated Summary
Comments (0)